LEADER 05736nam 2200637Ia 450 001 9910824532003321 005 20200520144314.0 010 $a1-281-37805-4 010 $a9786611378059 010 $a0-387-71518-5 024 7 $a10.1007/978-0-387-71518-6 035 $a(CKB)1000000000440697 035 $a(EBL)371390 035 $a(OCoLC)272308574 035 $a(SSID)ssj0000103540 035 $a(PQKBManifestationID)11131344 035 $a(PQKBTitleCode)TC0000103540 035 $a(PQKBWorkID)10070357 035 $a(PQKB)10199630 035 $a(DE-He213)978-0-387-71518-6 035 $a(MiAaPQ)EBC371390 035 $a(Au-PeEL)EBL371390 035 $a(CaPaEBR)ebr10284529 035 $a(CaONFJC)MIL137805 035 $a(PPN)127046402 035 $a(EXLCZ)991000000000440697 100 $a20070423d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAngiogenesis$b[electronic resource] $ean integrative approach from science to medicine /$fedited by William D. Figg, Judah Folkman 205 $a1st ed. 2008. 210 $aNew York, NY $cSpringer$dc2008 215 $a1 online resource (616 p.) 300 $aDescription based upon print version of record. 311 $a1-4899-9668-0 311 $a0-387-71517-7 320 $aIncludes bibliographical references and index. 327 $aPhysiological & Pathological Angiogenesis: Biology of the Angiogenic Process -- History of Angiogenesis -- Angiogenesis and Vascular Remodeling in Inflammation and Cancer: Biology and Architecture of the Vasculature -- Endothelial Cell Activation -- Pericytes, the Mural Cells of the Microvascular System -- Matrix Metalloproteinases and Their Endogenous Inhibitors -- Integrins in Angiogenesis -- Angiogenesis and Regulatory Proteins -- Fibroblast Growth Factor-2 in Angiogenesis -- Vascular Permeability/Vascular Endothelial Growth Factor -- Platelet-Derived Growth Factor -- Angiopoietins and Tie Receptors -- Basement Membrane Derived Inhibitors of Angiogenesis -- Angiostatin and Endostatin: Angiogenesis Inhibitors in Blood and Stroma -- Thrombospondins: Endogenous Inhibitors of Angiogenesis -- Molecular & Cellular Mechanisms of the Angiogenic Process -- Overview of Angiogenesis During Tumor Growth -- Hypoxic Regulation of Angiogenesis by HIF-1 -- Regulation of Angiogenesis by von Hippel Lindau Protein and HIF2 -- Nitric Oxide in Tumor Angiogenesis -- VEGF Signal Tranduction in Angiogenesis -- Delta-like Ligand 4/Notch Pathway in Tumor Angiogenesis -- Immune Cells and Inflammatory Mediators as Regulators of Tumor Angiogenesis -- Contribution of Endothelial Progenitor Cells to the Angiogenic Process -- Tumor Angiogenesis and the Cancer Stem Cell Model -- Targeting the Tumor Microenvironment (Stroma) for Treatment of Metastasis -- Functional Assessments of Angiogenesis -- Normalization of Tumor Vasculature and Microenvironment -- Targeted Drug Delivery to the Tumor Neovasculature -- Models for Angiogenesis -- Surrogates for Clinical Development -- Imaging of Angiogenesis -- Tumor Endothelial Markers -- Clinical Translation of Angiogenesis Inhibitors -- Overview and Clinical Applications of VEGF-A -- Protein Tyrosine Kinase Inhibitors as Antiangiogenic Agents -- Therapeutic Strategies that Target the HIF System -- The Clinical Utility of Bevacizumab -- Development of Thalidomide and Its IMiD Derivatives -- TNP-470: The Resurrection of the First Synthetic Angiogenesis Inhibitor -- Clinical Development of VEGF Trap -- Recent Advances in Angiogenesis Drug Development -- Combination of Antiangiogenic Therapy with Other Anticancer Therapies -- Immunotherapy of Angiogenesis with DNA Vaccines -- Challenges of Antiangiogenic Therapy of Tumors -- Pharmacogenetics of Antiangiogenic Therapy -- Angiogenesis in Health & Disease -- Angiogenesis in the Central Nervous System -- Lymphatic Vascular System and Lymphangiogenesis -- Ocular Neovascularization -- Angiogenesis and Pathology in the Oral Cavity -- Revascularization of Wounds: The Oxygen-Hypoxia Paradox -- Journeys in Coronary Angiogenesis -- Perspectives on the Future of Angiogenesis Research. 330 $aDr. Judah Folkman, ?father of angiogenesis?, (1933-2008) was the Director of the Vascular Biology Program, Andrus Professor of Pediatric Surgery, and Professor of Cell Biology at Harvard University's Boston Children's Hospital. In the 1971 issue of The New England Journal of Medicine, he proposed the theory that tumor growth is angiogenesis dependent. This premise was the basis of this field of research and has become the focus of scientists worldwide. Because of Folkman's discovery and research, the possibilities of antiangiogenic and angiogenic therapy have broadened beyond cancer to many noncancerous diseases. This book represents the first collection in a volume of which Dr. Folkman is co-editor. Dr. Folkman authored nearly 400 original papers and more than 100 book chapters. Dr. William Figg is the chief of the Molecular and Clinical Pharmacology Program at the National Cancer Institute, National Institutes of Health. Over the past 15 years, his laboratory and clinic at the NCI have focused on the development of angiogenesis inhibitors. Dr. Figg has published more than 380 publications. 606 $aNeovascularization 606 $aBlood$xCirculation 615 0$aNeovascularization. 615 0$aBlood$xCirculation. 676 $a612.13 701 $aFigg$b William D$01719957 701 $aFolkman$b M. Judah$01719958 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910824532003321 996 $aAngiogenesis$94118216 997 $aUNINA